Bolt Biotherapeutics, Inc. (BOLT) News
Filter BOLT News Items
BOLT News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
BOLT News Highlights
- BOLT's 30 day story count now stands at 2.
- Over the past 15 days, the trend for BOLT's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- BDC are the most mentioned tickers in articles about BOLT.
Latest BOLT News From Around the Web
Below are the latest news stories about BOLT BIOTHERAPEUTICS INC that investors may wish to consider to help them evaluate BOLT as an investment opportunity.
Bolt Biotherapeutics Reports First Quarter 2023 Financial Results and Provides Business UpdateComprehensive BDC-1001 clinical safety and efficacy data as a single agent and in combination with nivolumab, including RP2D, to be presented at ASCO 2023BDC-1001 Phase 2 program expected to initiate in 2023 in HER2+ colorectal, endometrial, gastroesophageal, and breast cancerCash balance of $171.0 million anticipated to fund key clinical milestones through 2025 REDWOOD CITY, Calif., May 11, 2023 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics, Inc. (Nasdaq: BOLT), a clinical-stage biopharmaceutical co |
Bolt Biotherapeutics to Present Clinical Data from Phase 1 Dose-Escalation Trial of BDC-1001 in HER2-Expressing Tumors at 2023 ASCO Annual MeetingComprehensive Phase 1 data at ASCO support initiation of two Phase 2 trialsREDWOOD CITY, Calif., April 26, 2023 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics, Inc. (Nasdaq: BOLT), a clinical-stage biopharmaceutical company pioneering novel immuno-oncology therapeutics for the treatment of cancer, today announced that it will present a poster with clinical data from its completed Phase 1 dose-escalation study of BDC-1001 at the 2023 American Society for Clinical Oncology (ASCO) Annual Meeting. The con |
Investors in Bolt Biotherapeutics (NASDAQ:BOLT) have unfortunately lost 47% over the last yearIt's easy to match the overall market return by buying an index fund. Active investors aim to buy stocks that vastly... |
Bolt Biotherapeutics Says Phase 1 Data Supports Advancing Into Phase 2 StudiesBolt Biotherapeutics Inc (NASDAQ: BOLT) reported topline data from the dose-escalation study of BDC-1001 in HER2-expressing solid tumors that support advancing into two Phase 2 studies. BDC-1001 was well tolerated at all dose levels and schedules evaluated, both as monotherapy and combined with Bristol Myers Squibb & Co (NYSE: BMY) Opdivo (nivolumab). Target drug exposure levels were achieved at or near the recommended Phase 2 dose (RP2D) by more frequent administration, including every other we |
Bolt Biotherapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business UpdatePositive topline data from BDC-1001 dose-escalation clinical study validates the ability of the Boltbody™ ISAC platform to generate anti-tumor activity with acceptable safetyBDC-1001 advances into a focused Phase 2 program commencing in 2023: a trial as monotherapy and in combination with nivolumab in colorectal, endometrial, and gastroesophageal cancers; and a second trial in breast cancer studying monotherapy and combination with pertuzumab (Perjeta®)BDC-3042 expected to enter clinic in 2023; |
Bolt Biotherapeutics Announces Positive Topline Data from BDC-1001 Phase 1 Dose-Escalation Trial in HER2-Expressing Tumors, Supporting Advancement to Phase 2 Clinical StudiesBDC-1001 elicited objective clinical responses, including multiple PRs and long-term stable disease, across a diverse set of solid tumor types in monotherapy and in combination with nivolumabData support selection of a recommended Phase 2 dose and advancement into Phase 2 studies in breast, colorectal, endometrial, and gastroesophageal cancersEntered into a new collaboration with Roche, as part of further BDC-1001 Phase 2 program expansion, supplying pertuzumab (Perjeta®) to evaluate in combinat |
Bolt Biotherapeutics to Present Preclinical Data for BDC-3042, a Dectin-2-Targeting Agonistic Antibody, at 2023 AACR Annual MeetingREDWOOD CITY, Calif., March 14, 2023 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immuno-oncology therapeutics for the treatment of cancer, today announced that it will present a poster with new preclinical data for BDC-3042, a Dectin-2-targeting agonistic antibody, at the upcoming American Association of Cancer Research (AACR) Annual Meeting 2023. The conference is being held at the Orange County Convention Center in Orland |
Bolt Biotherapeutics to Present at Cowen 43rd Annual Healthcare ConferenceREDWOOD CITY, Calif., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immuno-oncology therapeutics for the treatment of cancer, today announced that management will present a company overview at the Cowen 43rd Annual Healthcare Conference on Tuesday, March 7, 2023, at 2:50 p.m. EST (11:50 a.m. PST) in Boston, Mass. A live webcast of the presentation will be available on the Events and Presentations page of Bolt’s |
Bolt Biotherapeutics to Present at February Investor ConferencesREDWOOD CITY, Calif., Feb. 01, 2023 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immuno-oncology therapeutics for the treatment of cancer, today announced that management will participate in two upcoming conferences in February: Guggenheim Healthcare Talks 2023 Oncology DayFireside chat on Wednesday, Feb. 8 at 12:55 p.m. PST (3:55 p.m. EST) Virtual SVB Securities Global Biopharma Conference 2023Fireside chat on Thursday, Feb |
Here's Why We're Watching Bolt Biotherapeutics' (NASDAQ:BOLT) Cash Burn SituationEven when a business is losing money, it's possible for shareholders to make money if they buy a good business at the... |